Sotac Pharmaceuticals (NSE:SOTAC) Construction In Progress: ₹8.1 Mil (As of Sep. 2025)


NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
52 GF Score
Price ₹105.00
GF Value ₹110.01
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals Construction In Progress?

Sotac Pharmaceuticals NSE:SOTAC 52 Construction In Progress is ₹8.1 Mil as of Sep. 2025. GuruFocus rates NSE:SOTAC with a GF Score™ of 52/100 and a GF Value™ of ₹110.01 (Fairly Valued). The stock has 6 warning signs investors should review.

Sotac Pharmaceuticals's quarterly construction in progress declined from Sep. 2024 (₹86.2 Mil) to Mar. 2025 (₹2.0 Mil) but then increased from Mar. 2025 (₹2.0 Mil) to Sep. 2025 (₹8.1 Mil).

Sotac Pharmaceuticals's annual construction in progress increased from Mar. 2023 (₹0.4 Mil) to Mar. 2024 (₹51.2 Mil) but then declined from Mar. 2024 (₹51.2 Mil) to Mar. 2025 (₹2.0 Mil).

Sotac Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals Construction In Progress Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Construction In Progress
Get a 7-Day Free Trial 0.00 0.00 0.41 51.24 2.04

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.97 51.24 86.21 2.04 8.12
NSE:SOTAC
52GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotac Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹8.1 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Construction In Progress of ₹8.1 Mil as of Sep. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Construction In Progress too high?
Sotac Pharmaceuticals' current Construction In Progress is ₹8.1 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Construction In Progress compare to ZTS and UTHR?
Sotac Pharmaceuticals' Construction In Progress of ₹8.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Construction In Progress is ₹8.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹105.00 — trading 4.6% below its estimated fair value. The current Construction In Progress is ₹8.1 Mil. Sotac Pharmaceuticals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Construction In Progress is ₹8.1 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹105.00 is trading 4.6% below its estimated GF Value™ of ₹110.01. GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:SOTAC:

  • Construction In Progress: ₹8.1 Mil
  • GF Value™: ₹110.01 vs. price of ₹105.00 (4.6% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
52GF Score

Get the complete analysis for NSE:SOTAC

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹105.00
Price
₹110.01
GF Value